Adaptive Biotechnologies Corporation (ADPT)

Etorro trading 970x250
Adaptive Biotechnologies Corporation (ADPT) Logo

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Address: 1551 Eastlake Avenue East, Seattle, WA, United States, 98102

Adaptive Biotechnologies Corporation News and around…

Latest news about Adaptive Biotechnologies Corporation (ADPT) common stock and company :

Hedge Funds Aren’t Crazy About Adaptive Biotechnologies Corporation (ADPT) Anymore
18 Oct, 2021 Yahoo! Finance

Is Adaptive Biotechnologies Corporation (NASDAQ:ADPT) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

Interesting ADPT Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Adaptive Biotechnologies Corp (ADPT) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADPT options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Notable Adaptive Biotechnologies Insider Trades $460K In Company Stock
11 Oct, 2021 Yahoo! Finance

Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies (NASDAQ:ADPT), made a large buy and sell of company shares on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Harlan Robins exercised options to purchase 11,685 Adaptive Biotechnologies shares at a price of $6.32 per share for a total of $73,849 on October 8. They then sold their shares on succeeding transactions in the open market. They sold a

What Is The Ownership Structure Like For Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?
11 Oct, 2021 Yahoo! Finance

Every investor in Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) should be aware of the most powerful shareholder...

Chief Financial Officer Of Adaptive Biotechnologies Trades $395K In Company Stock
08 Oct, 2021 Yahoo! Finance

Chad Cohen, Chief Financial Officer at Adaptive Biotechnologies (NASDAQ:ADPT), made a large buy and sell of company shares on October 6, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Chad Cohen exercised options to purchase 10,000 Adaptive Biotechnologies shares at a price of $7.27 per share for a total of $72,700 on October 6. They then sold their shares on succeeding transactions in the open market. They sold at price

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
06 Oct, 2021 Yahoo! Finance

SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. East

Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
02 Oct, 2021 Yahoo! Finance

Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients New research demonstrates T-cell testing using T-cell receptor (TCR) repertoire characterization can distinguish natural SARS-CoV-2 infection from COVID-19 vaccine response Late-breaking data show TCR repertoire characterization is nearly two times more sensitive than the standard two-tiered testing (STTT) at identifying Lyme disease SEATTLE, Oct. 02, 2021 (GLOBE N

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
30 Sep, 2021 FinancialContent

Combined ID-IGHV report at time of diagnosis conveniently provides additional prognostic information while also enabling future MRD monitoring in patients

Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
21 Sep, 2021 FinancialContent

New Partnership with Youth Organization STEM Paths Innovation Network (SPIN) Seeds Next Generation of Local Biotech Talent

Chief Scientific Officer Of Adaptive Biotechnologies Trades $505.90 Thousand In Company Stock
16 Sep, 2021 Yahoo! Finance

Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies (NASDAQ:ADPT), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 15, Harlan Robins bought 11,685 Adaptive Biotechnologies shares at a price of $6.32 per share, for a total of $73,849. They then sold their shares on succeeding transactions in the open market at prices ranging from $36

Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
16 Sep, 2021 FinancialContent

Research demonstrates the ability of Adaptive’s immune medicine platform to distinguish natural infection from vaccine response and the ability to detect prior infection nearly 12 months after initial diagnosis in some patients

Adaptive Biotechnologies Insider Trades $1.67 Million In Company Stock
13 Sep, 2021 Yahoo! Finance

Chad Robins, CEO And Chairman at Adaptive Biotechnologies (NASDAQ:ADPT), made a large insider sell on September 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Robins sold 43,499 shares of Adaptive Biotechnologies at a price of $38.67 per share. The total transaction amounted to $1,671,496. Robins still owns a total of 1,673,461 of Adaptive Biotechnologies worth, $62,118,872. Adaptive Biotechnologies shares

Chief Financial Officer Of Adaptive Biotechnologies Trades $665.09 Thousand In Company Stock
10 Sep, 2021 Yahoo! Finance

Chad Cohen, Chief Financial Officer at Adaptive Biotechnologies (NASDAQ:ADPT), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Chad Cohen purchased 14,375 Adaptive Biotechnologies shares at prices ranging from $6.55 to $7.27 per share for a total of $97,756 on September 8. They then sold their shares on succeeding transactions in the open market. They sold at pri

Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
07 Sep, 2021 FinancialContent
First Week of April 2022 Options Trading For Adaptive Biotechnologies (ADPT)
26 Aug, 2021 FinancialContent

Investors in Adaptive Biotechnologies Corp (ADPT) saw new options become available this week, for the April 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Return on Capital Employed Insights for Adaptive Biotechnologies
20 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Adaptive Biotechnologies (NASDAQ:ADPT) brought in sales totaling $38.51 ...

Ultivue Announces New Independent Board Members
19 Aug, 2021 FinancialContent

Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Add Up The Pieces: VBK Could Be Worth $333
16 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $332.65 per unit.

3 Life Science Stocks Cathy Wood's Buying Hand Over Fist Right Now
15 Aug, 2021 FinancialContent

ARK Invest made multiple purchases of these stocks last week.

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
12 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access
10 Aug, 2021 Yahoo! Finance

Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an ongoing research collaboration to broaden patient participation in Adaptive's clinical studies. The initial two studies of the partnership involve Adaptive's T-Detect™ diagnostic test. T-Detect™ is under develop

Adaptive Biotechnologies Corporation (ADPT) Q2 2021 Earnings Call Transcript
05 Aug, 2021 FinancialContent

ADPT earnings call for the period ending June 30, 2021.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.60% and 20.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
04 Aug, 2021 FinancialContent

Diagnostics industry expert to lead commercialization of marketed products and drive global commercial expansion

Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results
04 Aug, 2021 FinancialContent
Unusual Options Activity Insight: Adaptive Biotechnologies
04 Aug, 2021 FinancialContent

Adaptive Biotechnologies (NASDAQ:ADPT) shares experienced unusual options activity on Wednesday. The stock price moved up to $37.34 ...

Adaptive Biotechnologies Corporation (ADPT) is a NASDAQ Common Stock listed in , ,

970x250